Dynavax Technologies
Presença
Dynavax Technologies é uma das ...
Dynavax Technologies é uma empresa listada sob o símbolo DVAX (US).
Executivos
Veja o organograma con seus 28 executivos principais
Biografias mais buscadas da Dynavax Technologies
- Ryan Spencer, Chief Executive Officer and Director
- Daniel Kisner, Director
- Brent MacGregor, Director
Criar um alerta
para seguir os movimentos de executivos da Dynavax Technologies.
Biotecnologia
Dynavax Technologies possui 2.284 concorrentes concorrentes Lonza (Suíça), Eurofins (Luxemburgo) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- Karius acaba de anunciar uma arrecadação de fundos de 100 milhões de dólares. (publicado em 3 de maio de 2024).
- Transcarent acaba de anunciar uma arrecadação de fundos de 126 milhões de dólares. (publicado em 2 de maio de 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (publicado em 2 de maio de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Dynavax Technologies
- RSS News Feeds | Dynavax Technologies Corporation
- Medigen's COVID-19 Vaccine Combined with Dynavax's CpG 1018 Adjuvant Receives Taiwan Government Subsidy with First Participant Dosed in Early October | Dynavax Technologies Corporation
- Clover Biopharmaceuticals Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate | Dynavax Technologies Corporation
- Dynavax Announces Appointment of New Board Member and Planned Retirement of Chief Financial Officer | Dynavax Technologies Corporation
- Press Releases | Dynavax Technologies Corporation
- Valneva and Dynavax Announce Commercial Supply Agreement for Inactivated, Adjuvanted COVID-19 Vaccine | Dynavax Technologies Corporation
- Dynavax to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference | Dynavax Technologies Corporation
- Dynavax Announces Grant to Scale up CpG 1018 Adjuvant Capacity to Support the Global COVID-19 Response | Dynavax Technologies Corporation
- Dynavax Announces Second Quarter 2020 Financial Results | Dynavax Technologies Corporation
- TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program in Purchase Agreement for up to $250 million in Milestone Payments plus Royalties on Future Net Sales | Dynavax Technologies Corporation
- View more press releases Close
Redes sociais sobre Dynavax Technologies
- Dynavax Technologies na Wikipedia, Google News e Yahoo Finance
- Dynavax Technologies na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Ryan Spencer 
Ligue para a Dynavax Technologies em +1 510...
